Ankit Mahadevia
2022
In 2022, Ankit Mahadevia earned a total compensation of $4.2M as Former President and Chief Executive Officer at Spero Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Bonus | $254,000 |
|---|---|
| Non-Equity Incentive Plan | $342,900 |
| Option Awards | $1,499,324 |
| Salary | $633,750 |
| Stock Awards | $1,499,998 |
| Other | $9,733 |
| Total | $4,239,705 |
Mahadevia received $1.5M in stock awards, accounting for 35% of the total pay in 2022.
Mahadevia also received $254K in bonus, $342.9K in non-equity incentive plan, $1.5M in option awards, $633.8K in salary and $9.7K in other compensation.
Rankings
In 2022, Ankit Mahadevia's compensation ranked 800th out of 5,510 executives tracked by ExecPay. In other words, Mahadevia earned more than 85.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 800 out of 5,510 | 86th |
Division Manufacturing | 363 out of 2,989 | 88th |
Major group Chemicals And Allied Products | 121 out of 1,342 | 91st |
Industry group Drugs | 108 out of 1,245 | 91st |
Industry Pharmaceutical Preparations | 80 out of 899 | 91st |
Source: SEC filing on September 1, 2023.
Mahadevia's colleagues
We found two more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2022.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019